RecruitingPhase 3NCT07172360
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Enrollment
420 participants
Start Date
Dec 26, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
- The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
- The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Exclusion Criteria3
- Those who may be allergic to VC005, similar drugs or their excipients.
- Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
- Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVC005 tablets
VC005 groups repeat administration for 48 weeks
DRUGVC005 Tablets Placebo
VC005 placebo groups repeat administration for 48 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07172360